Texas Health Resources Launches Ultrafiltration Therapy Using CHF Solutions’ Aquadex FlexFlow® System
July 16 2019 - 8:30AM
CHF Solutions (Nasdaq: CHFS) today announced that the Texas Health
Resources hospital system has initiated the offering of
ultrafiltration therapy using the company’s Aquadex FlexFlow
system.
“Heart failure continues to be an increasingly
urgent and unmet medical need in the United States, and the
management of fluid overload is an important issue to be addressed
with these patients,” said John Erb, chairman and CEO of CHF
Solutions. “The Aquadex FlexFlow System is designed to help
improve the quality of life of heart failure patients and to reduce
the burden on the healthcare system as a whole and we are pleased
to have the opportunity to provide the Texas Health Resources
system with our fluid management solution.” Texas Health Resources
is a faith-based, nonprofit health system that cares for more
patients in North Texas than any other provider. With a service
area that consists of 16 counties and more than 7 million people,
the system is committed to providing quality, coordinated care
through its Texas Health Physicians Group and 26 hospital locations
under the banners of Texas Health Presbyterian, Texas Health
Arlington Memorial, Texas Health Harris Methodist and Texas Health
Huguley. Texas Health access points and services, ranging from
acute-care hospitals and trauma centers to outpatient facilities
and home health and preventive services, provide the full continuum
of care for all stages of life. The system has more than 4,000
licensed hospital beds, 6,200 physicians with active staff
privileges and more than 25,000 employees. For more information
about Texas Health, call 1-877-THR-WELL, or
visit www.TexasHealth.org.
About CHF Solutions
CHF Solutions, Inc. (Nasdaq:CHFS) is a medical
device company focused on commercializing the Aquadex FlexFlow
system for aquapheresis therapy. The Aquadex FlexFlow system is
indicated for temporary (up to eight hours) ultrafiltration
treatment of patients with fluid overload who have failed diuretic
therapy and extended (longer than 8 hours) ultrafiltration
treatment of patients with fluid overload who have failed diuretic
therapy and require hospitalization. All treatments must be
administered by a healthcare provider, under physician
prescription, both of whom having received training in
extracorporeal therapies. The company's mission is to predict,
measure, and control patient fluid balance through science,
collaboration, and innovative medical technology. CHF Solutions is
a Delaware corporation headquartered in Minneapolis, Minnesota with
wholly owned subsidiaries in Australia and Ireland. The company has
been listed on the Nasdaq Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release may be
considered forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including without
limitation, statements relating to the company’s future sales and
marketing. Forward-looking statements are predictions, projections
and other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS:
INVESTORS:Claudia Napal
DraytonChief Financial Officer CHF Solutions,
Inc.952-345-4205ir@chf-solutions.com
-or-Bret Shapiro Managing Partner CORE
IR516-222-2560brets@coreir.com www.coreir.com
MEDIAJules Abraham JQA
Partners, Inc. 917-885-7378jabraham@jqapartners.com
Source: CHF Solutions, Inc.
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Mar 2024 to Apr 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Apr 2023 to Apr 2024